Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction (LIBerate-FH)

• ClinicalTrials.gov Identifier: NCT04797104
• Recruitment Status: Active, not recruiting
• First Posted: March 15, 2021
• Last Update Posted: November 4, 2022
• Sponsor: LIB Therapeutics LLC
• Collaborator: Medpace, Inc.
• Information provided by (Responsible Party): LIB Therapeutics LLC

Study Description

Brief Summary:

This study is to assess LDL-C reductions at Week 24 and the mean of Weeks 22 and 24 with monthly Q4W (≤31 days) dosing of LIB003 300 mg administered subcutaneously (SC) compared to placebo in patients 18 years or older with Heterozygous FH on stable diet and oral LDL-C lowering drug therapy.

Condition or disease	Intervention/treatment	Phase
Heterozygous Familial Hypercholesterolemia	Drug: lerodalcibep	Phase 3

Detailed Description:

A randomized, double-blind, placebo-controlled, Phase 3 study of 24 weeks duration. Approximately 600 males and females aged ≥18 years with clinical or genetic heterozygous FH who fulfill the inclusion and exclusion criteria will be enrolled. Patients will be randomized in a 2:1 ratio to LIB003 (400 patients) or placebo (200 patients) administered SC Q4W (≤31 days). The study will consist of a Screening Period and a Treatment Period. The total study duration will be up to 35 weeks which includes up to an 11-week Screening Period (which may include up to a 8-week washout) and 24 weeks of study drug treatment.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 450 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: Randomized double blind placebo controlled
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Masking Description: double blind to treatment (LIB003 or placebo) and lipid data
• Primary Purpose: Treatment
• Official Title: Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Heterozygous FH Patients on Stable Lipid-Lowering Therapy Requiring Additional LDL-C Reduction
• Actual Study Start Date: April 22, 2021
• Estimated Primary Completion Date: April 30, 2023
• Estimated Study Completion Date: May 31, 2023

Arms and Interventions

Arm	Intervention/treatment
Experimental: LIB003 (lerodalcibep); 300 mg (1.2 mL) SC Q4W	Drug: lerodalcibep; 300 mg Q4W; Other Name: LIB003
Placebo Comparator: Placebo; 1.2 mL SC Q4W	Drug: lerodalcibep; 300 mg Q4W; Other Name: LIB003

Outcome Measures

Primary Outcome Measures :

1. Change from baseline compared to placebo in LDL-C level [ Time Frame: 24 weeks ]
   LS mean percent change in LDL-cholesterol compared to placebo

Secondary Outcome Measures :

1. Incidence of Treatment-Emergent Adverse Events as assessed by Medical Dictionary for Regulatory Activities [ Time Frame: 24 weeks ]
   Incidence of Treatment-Emergent Adverse Events (TEAE) as assessed by Medical Dictionary for Regulatory Activities as mild, moderate or severe compared to placebo
2. Change in serum free PCSK9 with LIB003 compared to placebo [ Time Frame: 24 weeks ]
   Change in percent LS mean between LIB003 and placebo

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Provision of written and signed informed consent prior to any study-specific procedure;
• Weight of ≥40 kg (88 lbs) and body mass index (BMI) ≥17 and ≤42 kg/m2;
• Diagnosis of definite, probable or possible HeFH based either on clinical criteria (Simon Broome register criteria or Dutch Lipid Clinics [DLC] Network Criteria) or genotyping and at the defined eligibility visit (screening or post washout/stabilization)
• LDL-C ≥70 mg/dL (if very-high risk for CVD) or ≥100 mg/dL (if high risk for CVD) and TG ≤400 mg/dL while on stable lipid lowering oral drug therapy (eg, maximally tolerated statin with or without ezetimibe); Patients unable to tolerate approved doses of a statin may take lower than approved doses and less frequently than daily as long as the dose and dosing frequency is consistent.
• Patients with documentation of inability to tolerate any statin at any dose, or history of rhabdomyolysis, and unable to tolerate any other allowed oral lipid lowering agent, and thus on no lipid lowering therapy must have an LDL-C ≥190 mg/dL (4.9 mmol/L) at the Screening Visit unless they have a documented pathogenic FH variant;
• Stable diet and other lipid lowering oral therapies besides statins and ezetimibe including bile-acid sequestrants, OM-3 compounds, fenofibrate, bezafibrate, nicotinic acid and bempedoic acid or combinations thereof for at least 4 weeks
• Patients on a PCSK9 mAb at a dose of 75 mg, 140 mg, or 150 mg Q2W must undergo a washout period of ≥4 weeks after the last dose; for those on a dose of 300 mg or 420 mg Q4W (≤31 days) the washout period is ≥8 weeks following last dose;
• Females of childbearing potential must be using a highly effective form of contraception if sexually active and have negative urine pregnancy test at the last Screening Visit

Exclusion Criteria:

• Use of prohibited oral lipid lowering agents mipomersen or lomitapide within 6 months of screening, gemfibrozil within 6 weeks of the Screening Visit or LDL/plasma apheresis within 2 months prior to Day 1;
• Documented history of HoFH defined clinically or genetically
• History of any prior or active clinical condition or acute and/or unstable systemic disease compromising patient inclusion, at the discretion of the Investigator.
• Females of childbearing potential who are sexually active, not using or unwilling to use a highly effective form of contraception, pregnant or breastfeeding, or who have a positive urine pregnancy test at the last Screening Visit;
• Moderate to severe renal dysfunction, defined as an eGFR <30 mL/min/1.73m2
• Active liver disease or hepatic dysfunction, history of liver transplant, and/or AST or ALT >2.5 × the ULN
• Uncontrolled thyroid disease: hyperthyroidism or hypothyroidism as defined by TSH <LLN or >1.5 × ULN, respectively,
• Uncontrolled Type 1 or Type 2 DM (fasting glucose≥200 mg/dL or HbA1c of ≥9%;
• Planned cardiac surgery or revascularization;
• New York Heart Association III-IV heart failure
• Previous treatment with LIB003 or any adnectin product;
• Any other finding which, in the opinion of the Investigator, would compromise the patient's safety or participation in the study

Contacts and Locations

Locations

United States, Ohio

Metabolic & Atherosclerosis Research Center (MARC)

Cincinnati, Ohio, United States, 45227

Israel

Department of Medicine, Hadassah University Hospital

Jerusalem, Israel, 12000

Rabin Medical Center, Beilinson Hospital,

Petah Tikva, Israel, 49100

Norway

Lipid Clinic, Oslo University Hospital

Oslo, Norway, 0586

South Africa

Carbohydrate and Lipid Metabolism Research Unit

Johannesburg, Gauteng, South Africa, 2193

Division of Lipidology, Department of Medicine University of Cape Town

Cape Town, Western Province, South Africa, 7925

Turkey

Ege University Medical School

İzmir, Bornova, Turkey, 35040

Sponsors and Collaborators

LIB Therapeutics LLC

Medpace, Inc.

Investigators

• Study Director: David Kallend, MB BCh; LIB Therapeutics

More Information

• Responsible Party: LIB Therapeutics LLC
• ClinicalTrials.gov Identifier: NCT04797104
• Other Study ID Numbers: LIB003-004
• First Posted: March 15, 2021
• Last Update Posted: November 4, 2022
• Last Verified: November 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by LIB Therapeutics LLC:

lerodalcibep; PCSK9 inhibitor

Additional relevant MeSH terms:

Hyperlipoproteinemia Type II; Hypercholesterolemia; Hyperlipidemias; Dyslipidemias; Lipid Metabolism Disorders; Metabolic Diseases; Lipid Metabolism, Inborn Errors; Metabolism, Inborn Errors; Genetic Diseases, Inborn; Hyperlipoproteinemias